PATENT ASSIGNMENT COVER SHEET

EPAS ID: PAT6827643

Electronic Version v1.1
Stylesheet Version v1.2

 SUBMISSION TYPE:
 NEW ASSIGNMENT

 NATURE OF CONVEYANCE:
 ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
IVONA JASPRICA	05/03/2017
SABINA KESER	05/11/2017
KATARINA PINDRIC	05/15/2017

RECEIVING PARTY DATA

State/Country: Postal Code:	DENMARK DK-2300		
City:	KOBENHAVN S		
Street Address:	DALSLANDSGATE 11		
Name:	XELLIA PHARMACEUTICALS APS		

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17215675

CORRESPONDENCE DATA

Fax Number: (617)812-1277

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8042800449

Email: docketing@mcneillbaur.com, michelle.walsh@mcneillbaur.com

Correspondent Name: MCNEILL BAUR PLLC

Address Line 1: 125 CAMBRIDGE PARK DRIVE

Address Line 2: SUITE 301

Address Line 4: CAMBRIDGE, MASSACHUSETTS 02140

ATTORNEY DOCKET NUMBER: 01269-0001-04US

NAME OF SUBMITTER: MICHELLE S. WALSH

SIGNATURE: /Michelle S. Walsh/

DATE SIGNED: 07/22/2021

Total Attachments: 3

source=01269-0001-04US_Parent_Assignment#page1.tif source=01269-0001-04US_Parent_Assignment#page2.tif source=01269-0001-04US_Parent_Assignment#page3.tif

PATENT 506780826 REEL: 056949 FRAME: 0706

DECLARATION AND ASSIGNMENT

Title of Invention: Glycopeptide Compositions

As a below named inventor, I hereby declare that:

This declaration is directed to:

[X] the attached application (Attorney Docket Number OSA(034US), or

[] Patent application number filed on

[X] which claims priority to PCT/EP2015/075918 filed on November 6, 2015 Which claims the benefit of priority to US 62/076,400, filed November 6, 2014 and U.S. 62/168,749, filed on May 30, 2015.

The above-identified application was made or authorized to be made by me, and I have reviewed and understand the contents of the application, including the claims.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I am aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56.

Whereas, each undersigned inventor has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application (herein referred to as the "APPLICATION");

Whereas, XELLIA PHARMACEUTICALS APS, corporation established in the Country of Denmark, with an office at or having a place of business at Dalslandsgate 11, Kobenhavn S. DK-2300, Denmark (herein referred to as "ASSIGNEE"), desires to acquire or has acquired, and each undersigned inventor acknowledges the obligation to assign to ASSIGNEE, and the parties desire to use this Declaration and Assignment to memorialize the grant to ASSIGNEE of the entire worldwide right, title, and interest in and to the INVENTION including all embodiments thereof, and in and to any and all patent applications and patents directed thereto;

Now, therefore, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, each undersigned inventor (herein referred to as "ASSIGNOR") hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, and any and all other patent applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisions, continuations, continuations in-part, reissues, reexaminations, renewals, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. In addition, each undersigned inventor hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on said improvements or resulting therefrom to said ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by the undersigned had this Assignment not been made; and each undersigned inventor agrees to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns,

Each undersigned inventor also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Declaration and Assignment any further identification of the APPLICATION (including, but not limited to, patent Application Number and filing date, and Attorney Docket Number), and further grants ASSIGNEE, its successors, legal representatives, and assigns the right to execute confirmatory assignments on their behalf.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

	Jan V		422	Date: \\Osi\ \	
Name of Inve	ntor: IVONA	JASPRICA	V		
Witness.	(SC) 200	<i></i> p	rate: <u>0703/7</u> 4	X47 K.L.	Date: <u>\$540177</u> 7+

Page 1 of 3

O5A0034US (P24411USPC)

DECLARATION AND ASSIGNMENT

Title of Invention: Glycopeptide Compositions

As a below named inventor, I hereby declare	that	
This declaration is directed to:		
[X] the attached application (Attorney D	ocket Number OSA0034US), or	
[] Patent application number	filed on	
[X] which claims priority to PCT/EP201	5/075918 filed on November 6, 2011	\$
Which claims the benefit of priority	to US 62/076,400, filed November 6	i, 2014 and U.S. 62/168,749, filed
on May 30, 2015.		

The above-identified application was made or authorized to be made by me, and I have reviewed and understand the contents of the application, including the claims.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I am aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56.

Whereas, each undersigned inventor has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application (herein referred to as the "APPLICATION");

Whereas, XELLIA PHARMACEUTICALS APS, corporation established in the Country of Denmark, with an office at or having a place of business at Dalslandsgate 11, Kobenhavn S. DK-2300, Denmark (herein referred to as "ASSIGNEE"), desires to acquire or has acquired, and each undersigned inventor acknowledges the obligation to assign to ASSIGNEE, and the parties desire to use this Declaration and Assignment to memorialize the grant to ASSIGNEE of the entire worldwide right, title, and interest in and to the INVENTION including all embodiments thereof, and in and to any and all patent applications and patents directed thereto;

Now, therefore, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, each undersigned inventor (herein referred to as "ASSIGNOR") hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, and any and all other patent applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisions, cominuations, continuations-in-part, reissues, reexaminations, renewals, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. In addition, each undersigned inventor hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on said improvements or resulting therefrom to said ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by the undersigned had this Assignment not been made; and each undersigned inventor agrees to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

Each undersigned inventor also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Declaration and Assignment any further identification of the APPLICATION (including, but not limited to, patent Application Number and filing date, and Attorney Docket Number), and further grants ASSIGNEE, its successors, legal representatives, and assigns the right to execute confirmatory assignments on their behalf.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1(6)1 by fine or imprisonment of not more than five (5) years, or both. Signature: L. Pirdice Date: 15.05.617.

Name of Inventor: KATARINA PINDRIC

U.C. B. Co. Date: 15.05.12.

Witness: Witness: Date: 15.05.12.

Witness: Witness: Date: 15.05.617.

Page 3 of 3

OSA0034US (P24411USPC)

DECLARATION AND ASSIGNMENT

Title of Invention: Glycopeptide Compositions

As a bel	ow named inventor, I hereby declare	that	
	This declaration is directed to:		
{X}	the attached application (Attorney I	Jocket Number OSA0034US), or	
	Patent application number	filed on	
[X]	which claims priority to PCT/EP20	15/075918 filed on November 6, 2	015
	Which claims the benefit of priority	to US 62/076,400, filed November	er 6, 2014 and U.S. 62/168 749 filer
	on May 30, 2015.		and the second s

The above identified application was made or authorized to be made by me, and I have reviewed and understand the coments of the application, including the claims.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I am aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56.

Whereas, each undersigned inventor has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application (herein referred to as the "APPLICATION");

Whereas, XELLIA PHARMACEUTICALS APS, corporation established in the Country of Denmark, with an office at or having a place of business at Dalslandsgate 11, Kobenhavn S. DK-2300, Denmark (herein referred to as "ASSIGNEE"), desires to acquire or has acquired, and each undersigned inventor acknowledges the obligation to assign to ASSIGNEE, and the parties desire to use this Declaration and Assignment to memorialize the grant to ASSIGNEE of the entire worldwide right, title, and interest in and to the INVENTION including all embodiments thereof, and in and to any and all patent applications and patents directed thereto;

Now, therefore, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, each undersigned inventor (herein referred to as "ASSIGNOR") hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, and any and all other patent applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisions, continuations, continuations-in-part, reissues, reexaminations, renewals, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. In addition, each undersigned inventor hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on said improvements or resulting therefrom to said ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by the undersigned had this Assignment not been made; and each undersigned inventor agrees to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

Each undersigned inventor also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Declaration and Assignment any further identification of the APPLICATION (including, but not limited to, patent Application Number and filing date, and Attorney Docket Number), and further grants ASSIGNEE, its successors, legal representatives, and assigns the right to execute confirmatory assignments on their behalf.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature:	Salve lex	L	Date: // .	T. 2019.
Name of Inventor	: SABINA KESER			***************************************
	20	Date: 415/17.	Johann	Date: 41.5, 2017
Witness:			Witness:	A 1000
		Page 2	of 3	

PATENT REEL: 056949 FRAME: 0709

RECORDED: 07/22/2021